Cannabics Pharmaceuticals launches research program to develop melanoma treatment drug candidate

Cannabics Pharmaceuticals Inc., the Bethesda-based developer of cancer related cannabinoid-based medicine, Monday announced the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on Melanoma cell lines. The ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *